​Renato G. Martins, MD, MPH, discusses why nivolumab is not ready to move up to being a firstline treatment in non
Renato G. Martins, MD, MPH, Medical Director, Thoracic/Head and Neck Medical Oncology, Seattle Cancer Care Alliance, discusses nivolumab in nonsmall cell lung cancer (NSCLC). Martins says while there are a number of trials where nivolumab is being combined with chemotherapy to increase its efficacy, the treatment is not ready for the firstline. He says until there is a reliable biomarker to identify which patients would benefit from the treatment, it would be difficult to move nivolumab into the frontline.
Roundtable Roundup: Early CAR T-cell Therapy in Multiple Myeloma
May 19th 2025In separate live virtual events, Sarah A. Holstein, MD, PhD, and Shashank Cingam, MD, discuss options for a patient with relapsed/refractory multiple myeloma and the use of chimeric antigen receptor (CAR) T-cell therapy.
Read More